Racial and ethnic differences in warfarin response

Journal of Heart Valve Disease

Volumn 13, Issue 1, 2004, Pages 15-21

  Rouby, Soumaya El ^a   Mestres, Carlos A ^b   LaDuca, Frank M ^a   Zucker, Mareia L ^a  

^a ITC   (United States)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CYTOCHROME P450; WARFARIN;

COMPARATIVE STUDY; FOOD DRUG INTERACTION; GENETICS; HUMAN; METABOLISM; RACE; REVIEW;

ANTICOAGULANTS; CONTINENTAL POPULATION GROUPS; CYTOCHROME P-450 ENZYME SYSTEM; FOOD-DRUG INTERACTIONS; HUMANS; WARFARIN;

EID: 4344693542     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Chai SJ, Macik BG. Improving the safety profile of warfarin. Semin Hematol 2002;39:179-186 (Pubitemid 34793039)
2. Henderson MC, White RH. Anticoagulation in the elderly. Curr Opin Pulmon Med 2001;7:365-370 (Pubitemid 32929697)
3. Ananthasubramaniam K, Beattie JN, Rosman HS, Jayam V, Borzak S. How safely and for how long can warfarin therapy be withheld in prosthetic heart valve patients hospitalized with a major hem-orrhage? Chest 2001;119:478-484 (Pubitemid 32163760)
4. Bern MM, Bierbaum B, Wetzner S, Brennan W, McAlister S. Very low dose warfarin as prophylax-is against ultrasound detected deep vein thrombo-sis following primary hip replacement. Am J Hematol 2002;71:69-74
5. Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. Br Med J 2002;325:828-831
6. Haas S. Prevention of venous thromboembolism: Recommendations based on the International Consensus and the American College of Chest Physicians Sixth Consensus Conference on Antithrombotic Therapy. Clin Appl Thromb Hemost 2001;7:171-177 (Pubitemid 32574178)
7. Loebstein R, Yonath H, Peleg D, et al. Inter-individual variability in sensitivity to warfarin -Nature or nurture? Clin Pharmacol Ther 2001;70:159-164
8. Yu HC, Chan TY, Critchley JA, et al. Factors deter-mining the maintenance dose of warfarin in Chinese patients. Q J Med 1996;89:127-135 (Pubitemid 26053126)
9. Ageno W, Crowther M, Steidl L, et al. A. Low dose oral vitamin K to reverse acenocoumarol-induced coagulopathy: A randomized controlled trial. Thromb Haemost 2002;88:48-51 (Pubitemid 34759875)
10. Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino JS, Jr. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharma-codynamics: Enhanced safety of warfarin as a CYP2C9 probe. J Clin Pharmacol 2001;41:715-722 (Pubitemid 32612434)
11. Shetty HG, Fennerry AG, Routledge PA. Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy. Clin Pharmacokinet 1989;16:238-253 (Pubitemid 19114714)
12. Hathaway WE. Vitamin K deficiency. Southeast Asian J Trop Med Public Health 1993;24(suppl.l):5-9
13. Takahashi H, Echizen H. Pharmacogenetics of war-farin elimination and its clinical implications. Clin Pharmacokinet 2001;40:587-603 (Pubitemid 32758581)
14. Palareti G, Legnani C. Warfarin withdrawal. Pharmacokinetic- pharmacodynamic considera-tions. Clin Pharmacokinet 1996;30:300-313
15. Redman AR. Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dos-ing. Pharmacotherapy 2001;21:235-242 (Pubitemid 32119201)
16. .Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001,41:815-850 (Pubitemid 32385908)
17. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in-vitro and human data. Pharmacogenetics 2002;12:251-263 (Pubitemid 34596790)
18. Wong JY, Seah ES, Lee EJ. Pharmacogenetics: The molecular genetics of CYP2D6 dependent drug metabolism. Ann Acad Med Singapore 2000;29:401-406
19. Idle JR, Corchero J, Gonzalez FJ. Medical implica-tions of HGP's sequence of chromosome 22. Lancet 2000;355:319 (Pubitemid 30068538)
20. Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications 1999; Lancet 353:717-719
21. .De Morais SM, Schweikl H, Blaisdell J, Goldstein JA. Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. Biochem Biophys Res Commun 1993;194:194-201 (Pubitemid 23237919)
22. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalyzed by the R144C allelic variant of CYP2C9. Pharmacogenetics 199;44:39-42
23. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690-1698 (Pubitemid 34289221)
24. Daly AK, Day CP, Aithal GP, et al. CYP2C9 poly-morphism and warfarin dose requirements. Br J Clin Pharmacol 2002;53:408-409 (Pubitemid 34415598)
25. Furuya H, Fernandez-Salguero P, Gregory W, et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995;5:389-392 (Pubitemid 26010117)
26. Dickmann LJ, Rettie AE, Kneller MB, et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 2001;60:382-387 (Pubitemid 32678304)
27. Blann A, Hewitt J, Siddiqui F, Bareford D. Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0. Br J Haematol 1999;107:207-209 (Pubitemid 29500828)
28. .Yu HCM, Chan TYK, Critchley JAJH, Woo KS. Factors determining the maintenance dose of war-farin in Chinese patients. Q J Med 1996;89:127-135 (Pubitemid 26053126)
29. Andalibi P, Farsam H, Amanlou M, et al. Determination of dosage requirements of warfarin in Iranian patients using HPLC technique. J Clin Pharm Ther 1998;23:199-202 (Pubitemid 28502343)
30. Aynacioglu AS, Brockmoller J, Bauer S, et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for Phenytoin. Br J Clin Pharmacol 1999;48:409-415 (Pubitemid 29417726)
31. .Yamak B, Karagoz HY, Zorlutuna Y, Eralp A, Tasdemir O, Bayazit K. Low-dose anticoagulant management of patients with St. Jude Medical mechanical valve prostheses. Thorac Cardiovasc Surg 1993;41:38-42 (Pubitemid 23090268)
32. Takahashi H, Kashima T, Nomizo Y, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998;63:519-528 (Pubitemid 28277273)
33. Absher RK, Moore ME, Parker MH. Patient-specif-ic factors predictive of warfarin dosage require-ments. Ann Pharmacother 2002;36:1512-1517
34. Wang SL, Huang J Lai MD, Tsai JJ Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995;5:37-42
35. Yoon YR, Shon JH, Kim MK, et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 2001;51:277-280
36. Kim RB. Transporters and drug disposition. Curr Opin Drug Dis Dev 2000;3:94-101 (Pubitemid 30108195)
37. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the mul-tidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem Cytochem 1990;38:1277-1287 (Pubitemid 20266126)
38. Liggett S. Functional properties of human ß2-adrenergic receptor polymorphism. News Physiol Sci 1995;10:265-273
39. Yu DK. The contribution of P-glycoprotein to phar-macokinetic drug-drug interactions. J Clin Pharmacol 1999;39:1203-1211 (Pubitemid 30644000)
40. Rodriguez I, Abernethy DR, Woosley RL. P-glyco-protein in clinical cardiology. Circulation 1999;99:472-474
41. Kater AP, Peppelenbosch MP, Brandjes DPM, Lumbantobing M. Dichotomal effect of the Coumadin derivative warfarin on inflammatory sig-nal transduction. Clin Diagn Lab Immunol 2002;9:1396-1397 (Pubitemid 35283314)
42. Hosseine SJ, Farid R, Ghalighi MR, Feely J. Interethnic differences in drug protein binding and alpha 1 acid glycoprotein concentration. Ir J Med Sci 1995;164:26-27
43. Edeki T, Dillon-Moore B, He N, et al. Comparison of plasma protein binding of basic drugs in black and white individuals. Am J Ther 1996;3:611-615 (Pubitemid 26378199)
44. Demirkan K, Stephens MA, Newman KP, Self-TH. Response to warfarin and other oral anticoagulants: Effects of disease states. South Med J 2000;93:448-454 (Pubitemid 30366220)
45. Ginsberg JA, Crowther MA White RH, Ortel TL. Anticoagulation therapy. Hematology (Am Soc Hematol Educ Program) 2001;339-357
46. Kellett HA, Sawers JS, Boulton FE, Cholerton S, Park BK, Toft AD. Problems of anticoagulation with warfarin in hyperthyroidism. Q J Med 1986;58:43-51 (Pubitemid 16101940)
47. Stephens MA, Self TH, Lancaster D, Nash T. Hypothyroidism: Effect on warfarin anticoagula-tion. South Med J 1989;82:1585-1586
48. Michiels JJ, Schroyens W, Berneman Z, van der Planken M. Acquired von Willebrand syndrome type 1 in hypothyroidism: Reversal after treatment with thyroxine. Clin Appl Thromb Hemost 2001;7:113-115 (Pubitemid 32242186)
49. Munter G, Hershko C. Increased warfarin sensitiv-ity as an early manifestation of occult prostate can-cer with chronic disseminated intravascular coagulation. Acta Haematol 2001;105:97-99 (Pubitemid 32620109)
50. Fugh-Berman A. Herbs and dietary supplements in the prevention and treatment of cardiovascular dis-ease. Prev Cardiol 2000;Winter 3:24-32
51. Fugh-Berman A. Herb-drug interactions. Lancet 2000;355:134-138 (Pubitemid 30068565)
52. .Chesney CM, Elam MB, Herd JA, et al. Effect of niacin, warfarin, and antioxidant therapy on coagu-lation parameters in patients with peripheral arteri-al disease in the Arterial Disease Multiple Intervention Trial (ADMIT). Am Heart J 2000;140:631-636
53. Heck AM, DeWitt BA, Lukes AL. Potential interac-tions between alternative therapies and warfarin. Am J Health Syst Pharm 2000;57:1221-1227;quiz 1228-1230
54. Kuhn MA. Herbal remedies: Drug-herb interac-tions. Crit Care Nurse 2002;22:22-28,30,32;quiz 34-35
55. Vaes LP, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: Nature of the evi-dence. Ann Pharmacother 2000;34:1478-1482
56. Page RL, II, Lawrence JD. Potentiation of warfarin by dong quai. Pharmacotherapy 1999;19:870-876 (Pubitemid 29415843)
57. Chan TY. Interaction between warfarin and dan-shen (Salvia miltiorrhiza). Ann Pharmacother 2001;35:501-504 (Pubitemid 32260218)
58. Hoult JR, Paya M. Pharmacological and biochemi-cal actions of simple coumarins: Natural products with therapeutic potential. Gen Pharmacol 1996;27:713-722 (Pubitemid 26233347)
59. Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health Syst Pharm 1997;54:692-693 (Pubitemid 27136670)
60. Taylor JR, Wilt VM. Probable antagonism of war-farin by green tea. Ann Pharmacother 1999;33:426-428 (Pubitemid 29215809)
61. Sullivan DM, Ford MA, Boyden TW. Grapefruit juice and the response to warfarin. Am J Health Syst Pharm 1998;55:1581-1583 (Pubitemid 28405996)
62. Leung AY, Chow HC, Kwong YL, et al. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivi-ty in Chinese patients. Blood 2001;98:2584-2587
63. El Rouby S, Chan L, LaDuca FM, Zucker ML. Warfarin requirement and frequent INR monitoring in Chinese patients with prosthetic heart valve replacement. A multi center prospective trial demonstrates clinical efficacy of low dose therapy. Blood 2002;100:1068